Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines to help protect the world against infectious diseases. We operate with the highest level of quality, integrity and safety for the betterment of public health. Our proprietary CpG 1018 adjuvant powers our diversified infectious vaccine portfolio, which includes HEPLISAV B,

Lead the execution of formulation, compatibility, and process development studies to support phase appropriate development of Dynavax's drug product portfolio. Duties will include design and execution of programs, evaluation of data, recommendations on strategy, and authoring associated documentation. Oversee technical transfer efforts, process validation, and manufacturi